Foghorn Therapeutics Cuts ~40% Staff, Refocuses Pipeline
Foghorn Therapeutics will not advance FHD-909 with Lilly and will stop the Selective SMARCA2 degrader program. The company is cutting its workforce by approximately 40% and prioritizing proprietary programs, with expected cash runway into the second half of 2029.